Edition:
India

3SBio Inc says 601a approved by China FDA for clinical trials ​


Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - 3SBio Inc <1530.HK>:Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​. 

Company Quote

13.22
-0.1 -0.75%
24 May 2019